Navigation Links
Psychemedics Awarded Patent Fundamental To Hair Analysis Drug Testing
Date:1/24/2012

ACTON, Mass., Jan. 24, 2012 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) , hair testing pioneer and global leader for 25 years, announced today that the United States Patent Office issued a seventh patent, US No. 8,084,215, to the company.  This patent focuses on liquefying hair and releasing drugs trapped in the hair without destroying the drugs.  The new patented method can be used with a broad range of immunoassay screen techniques, mass spectrometry methods, and chromatographic procedures. 

(Logo:  http://photos.prnewswire.com/prnh/20111107/NE00639LOGO )

Raymond C. Kubacki, Chairman and Chief Executive Officer, said, "We are pleased to have received this patent which is fundamental to all hair analysis drug testing. This patent covers the efficient digestion of hair and release of the drugs without destroying the drugs---getting virtually 100% of the drug out of the hair. This is fundamental to hair analysis drug testing because if you cannot get the drugs out of the hair, the drugs cannot be measured."  Kubacki continued, "Our ability to successfully release drug analytes from hair enables us to accurately identify more drug users, setting Psychemedics apart from all other hair testing technologies."

Kubacki added, "Psychemedics Corporation has, for 25 years, offered the most effective hair testing technology based upon scientifically validated drug testing methods.  Receiving this patent demonstrates our on-going commitment to achieving the best possible test to accurately identify the greatest number of drug users."

About Psychemedics – Psychemedics (NASDAQ: PMD) is the world's leading drug testing company using hair for the detection of drugs of abuse. Psychemedics has been successfully operating for 25 years and thousands of corporations worldwide currently rely on Psychemedics' proprietary hair analysis technology for their pre-employment and employee drug screening.  Psychemedics' clients include over 10% of the Fortune 500, some of the largest police departments in America, six Federal Reserve Banks, and schools.  For more information, visit the Psychemedics website at www.psychemedics.com.

 

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995:  From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties.  In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning growth, earnings, profit margins, earnings per share, revenues, dividends, future business, new accounts, customer base, market share, test volume sales and marketing strategies, technological advantages and intellectual property protection) may be "forward looking" statements.  Actual results may differ from those stated in any forward-looking statements.  Factors that may cause such differences include but are not limited to risks associated with the expansion of the Company's sales and marketing network, development of markets for new products and services offered, the economic health of principal customers of the Company, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.

 

Contact: Raymond C. Kubacki, Chairman, President and CEO
(978) 206-8220


'/>"/>
SOURCE Psychemedics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. 2 research facilities awarded technology seeding grants
2. The Concord Consortium awarded multi-million dollar Google grant
3. Brigham and Womens Hospital awarded $9.6 million to study whole genome sequencing
4. Scripps Florida scientist awarded $3.4 million for HIV/AIDS research
5. Researchers awarded $3.2 million from NIH to pioneer advanced biomolecule discovery technology
6. Southampton professor awarded major funding for Biophotonics programme
7. UC Arlitt Center awarded NSF grant to research learning at PlayScapes
8. 200 thousand dollars awarded to genomics researchers to spark new research technology development
9. Marine Biological Laboratory Course Director Eric Davidson awarded International Prize for Biology
10. Scripps Research scientist awarded $500,000 grant to study Parkinsons disease
11. Researcher inspired by life in a glass house awarded £1.3 million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology: